Sino Biopharmaceutical Limited (HKEX: 1177) operates within the global healthcare and pharmaceutical sector. Its primary business activities encompass biopharmaceutical research, formulation development, clinical testing, and the large-scale commercial manufacturing and distribution of modern medicines across critical therapeutic areas, including oncology, infectious diseases, respiratory ailments, and metabolic disorders, serving millions of patients through extensive healthcare networks.